Point72 Asset Management

Point72 Asset Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Point72 Asset Management’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-639	Closed	-$1.56M	–	1057
2018 Q3	$1.56M	Sell	639 -2,839	-82%	-$6.64M	0.01%	787
2018 Q2	$7.45M	Buy	+3,478	New	+$5.04M	0.03%	511

Other funds holding GLMD

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Point72 Asset Management's GLMD Position: Q4 2018 in Review

Point72 Asset Management sold out of Galmed Pharmaceuticals (GLMD) in Q4 2018, closing a stake of 639 shares — an estimated $1.56M sold.

Point72 Asset Management first reported a position in GLMD in Q2 2018 and held it in 2 quarters. The position peaked at $7.45M in Q2 2018. 42 funds tracked by Wall St. Rank hold GLMD as of Q4 2018.

Point72 Asset Management reported no remaining Galmed Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Point72 Asset Management sold 639 Galmed Pharmaceuticals shares in Q4 2018, an estimated $1.56M.
Point72 Asset Management first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 2 quarters.
Point72 Asset Management's Galmed Pharmaceuticals position peaked at $7.45M in Q2 2018.
42 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2018.

Based on Point72 Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.